|
|
|
|
|
Flecainide
drug data and news
Flecainide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Flecainide | ||
| Brand Names/Synonyms | CCRIS 313; Flecaine; Flecainida [Inn-Spanish]; Flecainide; Flecainide Acetate; Flecainidum [Inn-Latin]; Tambocor | ||
| Indication | For the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disablin | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Flecainide, a hydantoin anticonvulsant, is used alone or with phenobarbital or other anticonvulsants to manage tonic-clonic seizures, psychomotor seizures, neuropathic pain syndromes including diabetic neuropathy, digitalis-induced cardiac arrhythmias, and cardiac arrhythmias associated with QT-interval prolongation. | ||
| Mechanism Of Action | Flecainide acts on sodium channels on the neuronal cell membrane, limiting the spread of seizure activity and reducing seizure propagation. The antiarrhythmic actions are mediated through effects on sodium channels in Purkinje fibers. | ||
| Flecainide News (When available) |
CVS probe finds prescription errors Feb 9, 2006 CVS to be monitored Feb 10, 2006 Probers accuse CVS pharmacies of errors Feb 10, 2006 Boehringer Ingelheim Announces 48-week Results from Aptivus(R) ... Feb 9, 2006 CVS probe finds prescription errors 09 Feb 2006 Boehringer Ingelheim Announces 48-week Results from Aptivus(R) ... 09 Feb 2006 Lexiva for the treatment of HIV infection in adults in combination ... Jan 19, 2006 FDA Approves Updated Labeling for LEXIVA Nov 18, 2005 Boehringer Ingelheim Announces 48-Week Results from Aptivus(R) ... Nov 21, 2005 Local anesthetics are effective for neuropathic pain Oct 26, 2005 Local Anesthetics Are Effective For Neuropathic Pain Oct 26, 2005 Heather Roy's Diary Aug 25, 2005 Prescription for trouble: Tot hospitalized after CVS goof Jul 11, 2005 Four-year-old hospitalized after being given wrong prescription Jul 12, 2005 Girl hospitalized after prescription error:- Jul 12, 2005 Study Results Presented on Pharmacokinetics of Once-Daily HIV ... Jul 26, 2005 Blunder by CVS sends Brockton child to hospital Jul 12, 2005 Prescription error rarity no comfort to victims Jul 16, 2005 Prone Positioning in Children With ARDS Positive Reflections on a ... Jul 12, 2005 Committee for Medicinal Products for Human Use Post-authorisation ... May 27, 2005 Radiofrequency Ablation May Be Feasible First-Line Treatment for ... Jun 2, 2005 Afib Recurs Less Often With Catheter-Based Ablation vs. Drugs May 31, 2005 Pharmacologic prophylaxis for postoperative atrial tachyarrhythmia ... May 9, 2005 New Pharmacokinetic Data on Co-Administration of the PI LEXIVA/r ... Apr 29, 2005 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antiarrhythmic Agents; Antiarrhythmic Agents; ATC:C01BC04 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Flecainide: Drug Interactions. TAMBOCOR has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects. During administration of multiple oral doses of TAMBOCOR to healthy subjects stabilized on a maintenance dose of digoxin, a 13%-19% increase in plasma digoxin levels occurred at six hours postdose. In a study involving healthy subjects receiving TAMBOCOR and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values. In this formal interaction study, TAMBOCOR and propranolol were each found to have negative inotropic effects; when the drugs were administered together, the effects were additive. The effects of concomitant administration of TAMBOCOR and propranolol on the PR interval were less than additive. In TAMBOCOR clinical trials, patients who were receiving beta blockers concurrently did not experience an increased incidence of side effects. Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized. Flecainide is not extensively bound to plasma proteins. In vitro studies with several drugs which may be administered concomitantly showed that the extent of flecainide binding to human plasma proteins is either unchanged or only slightly less. Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants ) would not be expected. TAMBOCOR has been used in a large number of patients receiving diuretics without apparent interaction. Limited data in patients receiving known enzyme inducers ( phenytoin, phenobarbital, carbamazepine ) indicate only a 30% increase in the rate of flecainide elimination. In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%. When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced. Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy; especially if these patients are extensive metabolizers. There has been little experience with the coadministration of TAMBOCOR and either disopyramide or verapamil. Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks. There has been too little experience with the coadministration of TAMBOCOR with nifedipine or diltiazem to recommend concomitant use. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N-(2-piperidylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)benzamide | ||
| Chemical Formula | C17H20F6N2O3 | ||
| Molecular Weight | 414.343 g/mol | ||
| Smiles String | C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 4.06 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 20 hours (range 12-27 hours) | ||
| Protein Binding [%] | 40% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Flecainide.html http://www.rxlist.com/cgi/generic2/flecainide.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00129 | ||
| CAS Registry Number | 54143-55-4 | ||
| KEGG Compound ID | C07001 | ||
| PubChem ID | SID:181803 | ||
| PharmGKB ID | PA449646 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 1966197 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |